Novavax Inc(NVAX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.08
Day High9.99
Open:9.68
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
NVAX
Tipranks
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
Tipranks
Novavax and Sanofi Advance Omicron JN.1 Booster With Completed Phase 3 Study
Tipranks
Novavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older Adults
StockStory
3 Cash-Burning Stocks We Think Twice About
IHRT
StockStory
Why Novavax (NVAX) Stock Is Trading Up Today
NVAX
StockStory
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
NVAX
Tipranks
Novavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should Watch
StockStory
3 Small-Cap Stocks That Fall Short
PTON
Motley Fool
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
StockStory
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
GDRX
StockStory
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call
NVAX
Motley Fool
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?
Tipranks
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS)
StockStory
Why Novavax (NVAX) Stock Is Trading Up Today
NVAX
Tipranks
Novavax Earnings Call: Partnerships, Cash Runway and Profit Path
Motley Fool
Novavax (NVAX) Q3 2025 Earnings Transcript
StockStory
Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars
NVAX
StockStory
Novavax (NVAX) Q1 Earnings Report Preview: What To Look For
NVAX

Profile

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.'Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.'Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.'ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.